Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1576-1584

  Desai, Prashant V ^a   Patny, Akshay ^a   Gut, Jiri ^c   Rosenthal, Philip J ^c   Tekwani, Babu ^a   Srivastava, Anuradha ^a   Avery, Mitchell ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIPARASITIC AGENT; ARTEMISININ; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; FALCIPAIN 2; FALCIPAIN 3; PENTAMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG CONFORMATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; IC 50; IN VITRO STUDY; INCIDENCE; LEISHMANIA DONOVANI; LEISHMANIASIS; MALARIA; NONHUMAN; PARASITOSIS; PHARMACOPHORE; TRYPANOSOMIASIS;

ANIMALS; ANTIMALARIALS; ANTIPARASITIC AGENTS; BINDING SITES; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DATABASES, FACTUAL; LEISHMANIA DONOVANI; MODELS, MOLECULAR; PLASMODIUM FALCIPARUM; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644854957     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0505765     Document Type: Article

References (48)

1. Lecaille, F.; Kaleta, J.; Bromme, D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 2002, 102, 4459-4488.
2. Brooks, D. R.; Hoberg, E. P. Parasite systematics in the 21st century: opportunities and obstacles. Trends Parasitol. 2001, 17, 273-275.
3. McKerrow, J. H. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. 1999, 29, 833-837.
4. Abath, F. G. Development of vaccines against human parasitic diseases: tools, current status and perspectives. Expert Opin. Invest. Drugs 2000, 9, 301-310.
5. WHO World Malaria Report; World Health Organization: Geneva, Switzerland, 2005.
6. Godai, T.; Nagera, J. Tropical Diseases; WHO Division of Control in Tropical Disease, World Health Organization: Geneva, Switzerland, 1990; pp 12-13.
7. WHO, Weekly Epidemiol. Rec. 2002, 77, 365-372.
8. The Leishmaniasis and Leishmania/HIV Co-Infections. Fact Sheet Number 116: World Health Organization: Geneva, Switzerland, 2000.
9. Sajid, M.; McKerrow, J. H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 2002, 120, 1-21.
10. Hernandez, A. A.; Roush, W. R. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol. 2002, 6., 459-465.
11. Shenai, B. R.; Sijwali, P. S.; Singh., A.; Rosenthal, P. J. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem. 2000, 275, 29000-29010.
12. Sijwali, P. S.; Shenai, B. R.; Gut, J.; Singh, A.; Rosenthal, P. J. Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem. J. 2001, 360, 481-489.
13. Desai, P. V.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. 2004, 47, 6609-6615.
14. Sijwali, P. S.; Rosenthal, P. J. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 2004. 101, 4384-4389.
15. Sijwali, P. S.; Kato, K.; Seydel, K. B.; Gut, J.; Lehman, J.; Klemba, M.; Goldberg, D. E.; Miller, L. H.; Rosenthal, P. J. Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8721-8726.
16. Shenai, B. R.; Lee, B. J.; Alvarez-Hernandez, A.; Chong, P. Y.; Emal, C. D.; Neitz., R. J.; Roush, W. R.; Rosenthal, P. J. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother. 2003, 47, 154-160.
17. Engel, J. C.; Doyle, P. S.; Hsieh, I.; McKerrow, J. H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 1998, 188, 725-734.
18. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
19. Huang, L.; Lee, A.; Ellman, J. A. Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J. Med. Chem. 2002, 45, 676-684.
20. Lee, B. J.; Singh, A.; Chiang, P.; Kemp, S. J.; Goldman, E. A.; Weinhouse, M. I.; Vlasuk, G. P.; Rosenthal, P. J. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother. 2003, 47, 3810-3814.
21. Batra, S.; Sabnis, Y. A.; Rosenthal, P. J.; Avery, M. A. Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. Bioorg. Med. Chem. 2003, 11, 2293-2299.
22. Chiyanzu, I.; Clarkson, C.; Smith, P. J.; Lehman, J.; Gut, J.; Rosenthal, P. J.; Chibale, K. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg. Med. Chem. 2005, 13, 3249-3261.
23. Chiyanzu, I.; Hansell, E.; Gut, J.; Rosenthal, P. J.; McKerrow, J. H.; Chibale, K. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg. Med. Chem. Lett. 2003, 13, 3527-3530.
24. Dominguez, J. N.; Leon, C.; Rodrigues, J.; Gamboa de Dominguez, N.; Gut, J.; Rosenthal, P. J. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J. Med. Chem. 2005. 48, 3654-3658.
25. Greenbaum, D. C.; Mackey, Z.; Hansell, E.; Doyle, P.; Gut, J.; Caffrey, C. R.; Lehrman, J.; Rosenthal, P. J.; McKerrow, J. H.; Chibale, K. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum. Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. 2004, 47, 3212-3219.
26. Sabnis, Y.; Rosenthal, P. J.; Desai, P.; Avery, M. A. Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors. J. Biomol. Struct. Dyn. 2002,19, 765-774.
27. Cazzulo, J. J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Changas desease. Curr. Top. Med. Chem. 2002, 2, 1261-1271.
28. Brinen, L. S.; Harwell, E.; Cheng, J.; Roush, W. R.; McKerrow, J. H.; Fletterick, R. J. A target within the target: probing cruzain's PI′ site to define structural determinants for the Chagas' disease protease. Struct. Folding Des. 2000, 8, 831-840.
29. Sabnis, Y. A.; Desai, P. V.; Rosenthal, P. J.; Avery, M. A. Probing the structure of falcipain-3, a cysteine protease from Plasmodium falciparum: comparative protein modeling and docking studies. Protein Sci. 2003, 12, 501-509.
30. Abagyan, R.; Totrov, M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 2001, 5, 375-382.
31. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 2000, 43, 4759-4767.
32. Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening-an overview. Drug Discovery Today 1998, 3, 160-178.
33. Elsevier MDL. http://www.md1.com.
34. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
35. aS in proteins. Biochemistry 1996, 35, 7819-7833.
36. Dixon, H. B.; Clarke, S. D.; Smith, G. A.; Carne, T. K. The origin of multiply sigmoid curves of pH-dependence. The partitioning of groups among titration pK values. Biochem. J. 1991, 278 (Part I). 279-284.
37. Fornabaio, M.; Cozzini, P.; Mozzarelli, A.; Abraham. D. J.; Kellogg, G. E. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes. J. Med. Chem. 2003, 46, 4487-4500.
38. Lipinski, C. A.; LombardoDominy, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
39. Proudfoot, J. R. The evolution of synthetic oral drug properties. Bioorg. Med. Chem. Lett. 2005, 15, 1087-1090.
40. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
41. Catalyst, version 4.9; Accelrys: San Diego, CA.
42. Patterson, D. E.; Cramer, R. D.; Ferguson, A. M.; Clark, R. D.; Weinberger, L. E. Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. J. Med. Chem. 1996, 39, 3049-3059.
43. Labriola, C.; Sousa, M.; Cazzulo, J. J. Purification of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi by affinity chromatography. Biol. Res. 1993, 26, 101-107.
44. Mikus, J.; Steverding, D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye alamar blue. Parasitol. Int. 2000, 48, 265-269.
45. Babich, H.; Borenfreund, E. Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl. Environ. Microbiol. 1991, 57, 2101-2103.
46. Gillmor, S. A.; Craik, C. S.; Fletterick, R. J. Structural determinants of specificity in the cysteine protease cruzain. Protein Sci. 1997, 6, 1603-1611.
47. Polgar, T.; Keseru, G. M. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. J. Med. Chem. 2005, 48, 3749-3755.
48. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 2005, 48, 1088-1097.